Now, Honigberg and colleagues describe an orally available, potent and selective inhibitor of the B-cell receptor (BCR) signalling molecule Bruton's tyrosine kinase (BTK), which shows promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback